Skip to main content
Premium Trial:

Request an Annual Quote

23andMe Cuts Some Staff

NEW YORK (GenomeWeb News) – California consumer genomics company 23andMe has confirmed that it has laid off some of its workers as part of an effort to maintain competitiveness and respond to a weak economy, the company said.

The firm did not say how many positions have been cut or what parts of the company were hit by the layoffs.

"We have reduced our staffing levels in a restructuring of our workforce," the company said in a statement. "This was a very difficult decision, but one that we felt was necessary to achieve 23andMe's long-term business development goals and maintain our strength in the industry.

"These cuts, which are a reflection of the current economic environment all companies are facing, will allow us to continue to invest in the growth of our Personal Genome Service and research endeavors," 23andMe said.

In June, the firm received a $2.6 million Series B investment from Google, which helped to back the company's 2007 launch with $3.9 million in Series A funding. The firm also has received financing from Google Co-founder, Sergey Brin, who is married to 23andMe Co-founder Anne Wojcicki.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.